Skip to main content

Table 1 Baseline characteristics of study patients

From: Intractable middle ear effusion in EGPA patients might cause permanent hearing loss: a case–control study

Characteristics Total (N = 75) MEE ( +) (N = 23) No MEE (N = 52) P-value
Age, years 45 (35–55) 40 (33–51) 47 (35–59) 0.085
Sex 0.602
 Male 36 (48.0) 10 (43.5) 26 (50.0)  
 Female 39 (52.0) 13 (56.5) 26 (50.0)  
Concurrent at diagnosis
 Asthma 73 (97.3) 23 (100) 50 (96.2) 1.000
 Peripheral neuropathy 56 (74.7) 16 (69.6) 40 (76.9) 0.499
 PNS abnormalities 56 (74.7) 20 (87.0) 36 (69.2) 0.104
 Extravascular eosinophils 50 (66.7) 15 (65.2) 35 (67.3) 0.859
 Peripheral eosinophilia 38 (50.7) 13 (56.5) 25 (48.1) 0.500
Major organ involvement
 Lung 36 (48.0) 12 (52.2) 24 (46.2) 0.630
 Heart 11 (14.7) 2 (8.7) 9 (17.3) 0.486
 Gastrointestinal tract 9 (12.0) 3 (13.0) 6 (11.5) 1.000
 Kidney 2 (2.7) 0 2 (3.6) 1.000
 Brain 2 (2.7) 0 2 (3.6) 1.000
Laboratory findingsa
 Eosinophil counts (/μL) 4430 (1746–7110) 4892 (1791–7198) 3875 (1381–7000) 0.861
  ≥ 5000 /μL 33 (44.0) 8 (34.8) 25 (48.1) 0.285
 ESR (mm/h) 21 (10–39) 28 (18–57) 16 (8–39) 0.044
 CRP (mg/dL) 0.6 (0.1–2.1) 1.2 (0.1–3.6) 0.5 (0.1–1.9) 0.048
 ANCA 10 (13.9) 0 10 (18.5) 0.024
 Total IgE (kU/L) 397 (130–1236) 710 (281–1596) 396 (92–943) 0.740
 ECP (ug/L) 52 (17–201) 45 (17–114) 59 (17–201) 0.861
Systemic treatment regimen 0.778
 Cyclophosphamide 57 (76.0) 17 (73.9) 40 (76.9)  
 Steroid only 18 (24.0) 6 (26.1) 12 (23.1)  
  1. Data are presented as number (percentage) or median (interquartile range)
  2. ANCA, Antineutrophil cytoplasmic antibody; CRP, C-reactive protein; ECP, Eosinophil cationic protein; EGPA, Eosinophilic granulomatosis with polyangiitis; ESR, Erythrocyte sedimentation rate; MEE, Middle ear effusion; PNS, paranasal sinus
  3. aMissing numbers are as follows; 2 patients had no data for ESR and ANCA, 4 for CRP, 16 for total IgE, and 21 for ECP